Delivery Module for Delivering Biotherapeutics Throughout the Body

Tech ID: 25541 / UC Case 2015-842-0


Researchers at the University of California, Davis have developed a robust and broadly applicable system for the delivery of peptide and oligonucleotide biotherapeutics.

Full Description

As the potential of protein- and gene-based therapies for the treatment or prevention of inherited and acquired diseases continues to be realized, the need for developing delivery systems for these treatments continues to grow. Multiple barriers impede the delivery of therapeutic biomolecules, such as polypeptides and polynucleotides, to specific target cells and tissues in vivo. Current delivery methods are unable to effectively deliver therapeutic biomolecules to target tissues such as the brain or other tissues. Newer methods, which include viral vectors and nanoparticles, have met with limited success, because they have limited dispersion and must be physically placed into the region of interest.

Researchers at the University of California, Davis have developed a protein-based delivery system for delivering biotherapeutics throughout the body. The combination of a cell penetrating peptide, a solubilizing peptide, and an aggregating peptide linked to a biotherapeutic such as a polypeptide or polynucleotide enables transport into a target cell or tissue. The novel combination of peptides into a delivery conjugate stabilizes the conjugate within the body and enables the internalization of the therapeutic payload into the cell or tissue. This dynamic protein based delivery system for peptide and nucleotide therapeutics potentially overcomes many limitations of current delivery systems. This system will potentially allow for either universal or specific delivery, even to tissues that are difficult to target such as the brain, while accommodating multiple routes of administration.


  • Cell- or tissue-specific delivery of a polypeptide or polynucleotide therapeutic effector moieties


  • Delivery to challenging target tissues such as the brain
  • Delivery moiety is easily conjugated to several classes of biotherapeutics
  • Delivery conjugate can be administered intraperitoneally, subcutaneously, intravenously, or intracranially

Patent Status

Country Type Number Dated Case
United States Of America Published Application 20180346531 12/06/2018 2015-842


Learn About UC TechAlerts - Save Searches and receive new technology matches


  • Pyles, Benjamin

Other Information


CPP, cell penetrating peptide, blood brain barrier delivery, solubilizing peptide, drug delivery

Categorized As